오하이오의 지방간질환 임상 시험
지방간질환 관련 연구 15개가 오하이오 내 여러 지역에서 참여자를 모집하고 있습니다.
오하이오의 도시
공식 연구 텍스트(영어)
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, Cleveland
피험자 모집 중2상
18세 ~ 70세 · 모든 성별 · 2026. 11. 13. 업데이트됨 · NCT06613698A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Akron
- Akero Clinical Study Site, Brooklyn
- Akero Clinical Study Site, Springboro
- 외 1개
피험자 모집 중3상
18세 ~ 80세 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT06528314A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Akron Gastro Research, Akron
- Digestive Specialists, Dayton
- Dayton Gastroenterology - Englewood, Dayton
- 외 2개
피험자 모집 중2상
18세 ~ 75세 · 모든 성별 · 2026. 11. 9. 업데이트됨 · NCT07288138A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Springboro
- GSK Investigational Site, Westlake
피험자 모집 중3상
18세 ~ 75세 · 모든 성별 · 2026. 11. 5. 업데이트됨 · NCT07704892A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Westlake
피험자 모집 중3상
18세 ~ 75세 · 모든 성별 · 2026. 11. 5. 업데이트됨 · NCT07701993Evaluation of Non-Invasive Tests for Metabolic Liver Disease
- Ohio Clinical Trials, Columbus
피험자 모집 중관찰 연구
18세 ~ 75세 · 모든 성별 · 2026. 10. 26. 업데이트됨 · NCT07122700A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Akron
- 89bio Clinical Study Site, Cincinnati
- 89bio Clinical Study Site, Cleveland
- 외 5개
피험자 모집 중3상
18세 ~ 75세 · 모든 성별 · 2026. 10. 23. 업데이트됨 · NCT06419374A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Akron
- 89bio Clinical Study Site, Dayton
- 89bio Clinical Study Site, Dayton
- 외 4개
피험자 모집 중3상
18세 ~ 80세 · 모든 성별 · 2026. 10. 23. 업데이트됨 · NCT06318169A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Akron Gastro Research, Akron
- Dayton Gastroenterology - Beavercreek, Beavercreek
- Clinical Research Institute of Ohio - Brooklyn, Brooklyn
- 외 1개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 8. 업데이트됨 · NCT07165028Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
- Cleveland Clinic, Cleveland
피험자 모집 중2상
18세 ~ 75세 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT05832229Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)
- Cincinnati Children's Hospital Medical Center, Cincinnati
피험자 모집 중2상
5세 ~ 16세 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT06133101A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, Akron
- GSK Investigational Site, Springboro
피험자 모집 중3상
18세 ~ 75세 · 모든 성별 · 2026. 9. 17. 업데이트됨 · NCT07221188Fibrosis Lessens After Metabolic Surgery
- Cleveland Clinic, Cleveland
피험자 모집 중4상건강한 지원자 환영
18세 ~ 75세 · 모든 성별 · 2026. 7. 31. 업데이트됨 · NCT06374875A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Akron
- GSK Investigational Site, Springboro
- GSK Investigational Site, Westlake
피험자 모집 중3상
18세 ~ 75세 · 모든 성별 · 2026. 7. 27. 업데이트됨 · NCT07221227Milk Thistle Clinical Trial in Pediatric NAFLD
- University Hospitals Cleveland Medical Center, Cleveland
피험자 모집 중2상
9세 ~ 22세 · 모든 성별 · 2026. 1. 27. 업데이트됨 · NCT06477146ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.